Smith R A
American Cancer Society, Atlanta, GA, USA.
CA Cancer J Clin. 2000 Sep-Oct;50(5):312-36. doi: 10.3322/canjclin.50.5.312.
In the hope of resolving underlying policy questions related to the value of breast cancer screening with mammography for women younger than 50 years of age, the National Institutes of Health and the National Cancer Institute in 1997 jointly sponsored a consensus conference on the subject. While the panel concluded that the data were insufficient to endorse mammography for this age group apart from individual choice, the conclusion was not the "consensus" sought by many of those with strong opinions on both sides of this issue, and the debate raged on. Prior to the 1997 conference, and since, meta-analyses of trial data and assessments of service screening programs have indicated that breast cancer screening with mammography for women between 40 and 49 meets recommended levels of performance compared with performance in women 50 years and older, especially if programs achieve high quality and screen at 12-to-18 month intervals. Because the detectable preclinical phase is shorter in younger women who develop breast cancer compared with that in women 50 years of age or older, a key component of any screening program for those younger than 50 is an appropriate screening interval. Many of the screening programs that had historically been developed for women in their forties--and whose disappointing results contributed to the confusion and controversy about the efficacy of mammography in younger women--had a 24-month screening interval, which was not found to be of significant benefit for early detection of breast cancer in this age group. While a new emphasis of this controversy has focused on the balance of benefits and harms in women ages 40 to 49, women of all ages need to be fully informed about the benefits and limitations of breast cancer screening--more specifically, what to expect at the time of screening, and what to expect from screening. There are differences in the performance and effectiveness of mammography in different age groups of women aged 40 and older, but these differences are not so great to question the value of screening in any one group. While some questions remain unresolved, the efficacy of mammography in women ages 40 to 49 should no longer be considered controversial.
为了解决与50岁以下女性乳腺钼靶筛查价值相关的潜在政策问题,美国国立卫生研究院和美国国立癌症研究所于1997年联合主办了一次关于该主题的共识会议。尽管专家组得出结论,除个人选择外,现有数据不足以支持对该年龄组进行乳腺钼靶筛查,但这一结论并非该问题双方许多持强硬观点者所寻求的“共识”,争论仍在激烈进行。在1997年会议之前及之后,对试验数据的荟萃分析和对服务性筛查项目的评估表明,40至49岁女性进行乳腺钼靶乳腺癌筛查与50岁及以上女性相比,达到了推荐的性能水平,特别是如果项目达到高质量且筛查间隔为12至18个月。由于患乳腺癌的年轻女性的可检测临床前期比50岁及以上女性短,任何针对50岁以下女性的筛查项目的一个关键组成部分是合适的筛查间隔。历史上为四十多岁女性制定的许多筛查项目——其令人失望的结果导致了对年轻女性乳腺钼靶筛查效果的困惑和争议——筛查间隔为24个月,而这一间隔被发现对该年龄组乳腺癌的早期检测没有显著益处。虽然这场争议的新焦点集中在40至49岁女性的利弊平衡上,但所有年龄段的女性都需要充分了解乳腺癌筛查的益处和局限性——更具体地说,筛查时会发生什么,以及从筛查中能期待什么。40岁及以上不同年龄组女性的乳腺钼靶检查在性能和有效性方面存在差异,但这些差异并不大到质疑任何一组筛查的价值。虽然一些问题仍未解决,但40至49岁女性乳腺钼靶筛查的有效性不应再被视为有争议的。